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Huntingtin-interacting protein 1 (HIP1) and HIP12
are orthologues of Sla2p, a yeast protein with essential
functions in endocytosis and regulation of the actin cy-
toskeleton. We now report that HIP1 and HIP12 are
major components of the clathrin coat that interact but
differ in their ability to bind clathrin and the clathrin
adaptor AP2. HIP1 contains a clathrin-box and AP2 con-
sensus-binding sites that display high affinity binding to
the terminal domain of the clathrin heavy chain and the
ear domain of the AP2  subunit, respectively. These
consensus sites are poorly conserved in HIP12 and cor-
respondingly, HIP12 does not bind to AP2 nor does it
demonstrate high affinity clathrin binding. Moreover,
HIP12 co-sediments with F-actin in contrast to HIP1,
which exhibits no interaction with actin in vitro. De-
spite these differences, both proteins efficiently stimu-
late clathrin assembly through their central helical do-
main. Interestingly, in both HIP1 and HIP12, this
domain binds directly to the clathrin light chain. Our
data suggest that HIP1 and HIP12 play related yet
distinct functional roles in clathrin-mediated
endocytosis.
Huntington disease, a neurological disorder characterized by
selective loss of striatal and cortical neurons and manifest
clinically by chorea and intellectual decline, results from poly-
glutamine expansion of huntingtin into the pathologic range of
beyond 35 repeats. In an effort to understand the disease
mechanism, several groups have identified proteins that asso-
ciate with huntingtin. One such protein, HIP1, was identified
in a yeast two-hybrid screen (1, 2). Binding of HIP1 to hunting-
tin is dramatically reduced following polyglutamine expansion,
strongly implicating this interaction in the disease process.
Subsequent to the identification of HIP1, a highly related pro-
tein (HIP12/HIP1R) was identified based on its homology to
HIP1 (3–5). In contrast to HIP1, HIP12 does not bind directly
to huntingtin (5).
HIP1 and HIP12 are orthologues of yeast Sla2p, a protein
that functions in both endocytosis and regulation of the actin
cytoskeleton (6–9). Each of these proteins contains an ENTH
(epsin N-terminal homology) domain that is thought to be
involved in clathrin-mediated endocytosis through binding to
phosphatidylinositol 4,5-bisphosphate-containing membranes
(10–13). The central portion of these proteins consists of a
helical domain with a high probability to form coiled-coil inter-
actions, followed by a C-terminal talin-homology domain. The
talin-homology domain has been shown to bind F-actin in Sla2p
and HIP12 suggesting a function in linking membrane attach-
ment and clathrin-coated vesicle (CCVs)1 formation with actin
dynamics (4, 14).
Recent studies have shown that both HIP1 and HIP12 are
enriched on clathrin-coated pits and CCVs and co-localize with
markers of endocytosis including clathrin, the clathrin adaptor
AP2 and Rab5 (4, 15–17). HIP1 binds directly to the terminal
domain of the clathrin heavy chain through a type I clathrin box
with the sequence LMDMD and to the ear domain of the 
subunit of AP2 (15–17). Moreover, a fragment of HIP1 containing
the clathrin and AP2-binding sites blocks clathrin-mediated en-
docytosis (15, 17).
To further characterize the roles of HIP1 and HIP12 in
clathrin-mediated endocytosis, we analyzed and compared the
protein interaction and functional properties of these two pro-
teins. Here, we report that HIP1 strongly associates with CCVs
but unlike HIP12, does not bind directly to F-actin. In contrast,
HIP12 does not demonstrate high affinity binding to clathrin
and AP2 as seen for HIP1. However, HIP1 and HIP12 both bind
directly to the clathrin light chain through their central helical
domain that interestingly, stimulates clathrin assembly. These
results suggest related but distinct functions for HIP1 and
HIP12 in clathrin-mediated endocytosis and identify a novel
interaction with clathrin light chain that appears to contribute
to clathrin assembly.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—Rabbit polyclonal antibodies against HIP1
(HIP1FP) and HIP12 (HIP12FP) and a mouse monoclonal antibody
against HIP1 (mAb HIP no. 9) were previously described (5, 15). Mono-
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clonal antibodies against the clathrin heavy chain and -adaptin were
purchased from Transduction Laboratories. Monoclonal antibody
against the clathrin light chain was purchased from Santa Cruz. Mono-
clonal antibodies against the FLAG, HA, and His6 epitopes were pur-
chased from Sigma, Roche Molecular Biochemicals, and Qiagen,
respectively.
DNA Constructs and Recombinant Proteins—Mammalian expression
constructs encoding full-length HIP1 and HIP12 and the talin homology
domain of HIP1, each with a FLAG epitope tag at the C terminus, were
previously described (5, 15). A construct encoding human full-length
HIP12 with a C-terminal HA epitope tag was generated by insertion of
a cDNA sequence, 5-GGAGGTGGATATCCCTATGATGTCCCCGATT-
ATGCC, encoding a linker of 3 glycines followed by the HA tag. The
integrity of the HA-tagged HIP12 construct was verified by DNA se-
quencing. Bacterial fusion proteins encoding His6-tagged terminal do-
main of the clathrin heavy chain and the amino acids 276–335 of HIP1
fused to GST (GST-HIP1-(276–335)) were previously described (15). A
His6-tagged construct encoding full-length clathrin light chain b was
generated by subcloning the GFP-clathrin light chain b cDNA (kindly
provided by Dr. Juan Bonifacino) into the pTrcHisB bacterial expres-
sion vector (Qiagen). The following HIP1 and HIP12 GST fusion pro-
teins were created by PCR amplification from either full-length HIP1 or
HIP12 cDNAs with subsequent cloning into pGEX-2T or pGEX-4T
vectors (Amersham Biosciences): GST-HIP12-(302–348), GST-HIP1-
(336–610), GST-HIP12-(349–644), GST-HIP1-(731–1003) (GST-HIP1-
talin), and GST-HIP12-(765–1068) (GST-HIP12-talin).
Pull-down Assays—Rat brains were homogenized in buffer A (10 mM
HEPES-OH, pH 7.4, 0.83 mM benzamidine, 0.23 mM phenylmethylsul-
fonyl fluoride, 0.5 g/ml aprotinin, and 0.5 g/ml leupeptin) and the
homogenates were centrifuged at 205,000 gmax for 30 min at 4 °C. The
supernatant (cytosolic extract) was collected and Triton X-100 was
added to 1% final concentration. Aliquots of the extract (2 mg) were
incubated overnight at 4 °C with GST fusion proteins pre-coupled to
glutathione-Sepharose beads. After incubation, samples were washed
three times in buffer A containing 1% Triton X-100. For binding exper-
iments, purified His6-tagged clathrin terminal domain or clathrin light
chain b fusion proteins (15 g) in buffer A were incubated overnight at
4 °C with various GST fusion proteins pre-coupled to glutathione-
Sepharose beads. After incubation, samples were washed three times in
buffer A. In all cases, proteins specifically bound to the beads were
eluted with gel sample buffer and analyzed by SDS-PAGE and Western
blot.
For pull-downs from transfected cells, HeLa cells were grown on
10-cm2 dishes and transfected with 6 g of HIP1 or HIP12 cDNA using
FuGENE (Roche Molecular Biochemicals). Twenty-four h post-transfec-
tion, cells were washed twice with ice-cold phosphate-buffered saline
(PBS) and lysed in buffer A (containing 1% Triton X-100 and 10 M Pefa
(Roche Molecular Biochemicals). Samples were incubated overnight at
4 °C with GST fusion proteins pre-coupled to glutathione-Sepharose
beads. After incubation, samples were washed three times in buffer A
containing 1% Triton X-100 and 10 M Pefa. Bound proteins were
analyzed by SDS-PAGE and transferred to nitrocellulose for Western
blot analysis.
Immunoprecipitation Assays—HEK-293T cells were grown on 10-
cm2 plates and transfected with 4 g of HIP12 cDNA by CaPO4
 pre-
cipitation. Transfected and nontransfected cells were washed 24 h
post-transfection with ice-cold PBS and lysed in ABL buffer (20 mM
Tris-Cl, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100) supple-
mented with a 1:100 dilution of aprotinin (Sigma), 20 ng/ml leupeptin
(Roche Molecular Biochemicals), and 10 M Pefa. The cell lysates were
sonicated and centrifuged at 245,000 gmax for 15 min. The supernatants
were then incubated for 6 h at 4 °C with mouse monoclonal antibody HIP1
no. 9 pre-bound to protein G-Sepharose (Amersham Biosciences). Subse-
quently, samples were washed 6 times in ABL buffer and specifically
bound proteins were analyzed by SDS-PAGE and Western blot.
Immunofluorescence—Cells were plated onto gelatinized glass slides
in 6-well tissue culture plates and transfected with 1 g of HIP1 or
HIP12 cDNA. Twenty-four h post-transfection, the cells were washed in
PBS, fixed in PBS containing 4% paraformaldehyde for 15 min at room
temperature, and permeabilized in PBS containing 0.3% Triton X-100
and 1% paraformaldehyde for 5 min. The cells were then incubated in
PBS containing 3% normal goat serum for 30 min to block nonspecific
binding. Depending on the experiment, the cells were then incubated
with monoclonal antibodies against the FLAG or HA epitopes for 1 h at
room temperature or overnight at 4 °C with a polyclonal antibody
against HIP1, followed by a 1-h incubation at room temperature with
appropriate secondary antibodies in PBS containing 2% normal goat
serum. Staining of the actin cytoskeleton was achieved by incubation
with Texas Red-phalloidin. Cells were then extensively washed in PBS,
mounted, and observed on a BioRad Radiance Plus confocal microscope
(BioRad, Hercules, CA) using Laser Sharp software (BioRad).
Actin-binding Assays—Purified human non-muscle monomeric actin
(Cytoskeleton Inc.) was polymerized as described previously (4) and
incubated with purified GST-HIP1-talin and GST-HIP12-talin (20 g
each) for 1 h at room temperature in a final volume of 50 l. The
samples were then centrifuged for 30 min at 362,000  gmax. Protein
components of the pellets and supernatants were analyzed by SDS-
PAGE followed by Coomassie Blue staining. Gels were scanned on a
ScanJet 6300 (Hewlett Packard) and protein amounts were determined
using Quantity One (Bio-Rad) software. Statistical analysis was done
by the Student’s t test.
Clathrin Purification and Clathrin Assembly Assays—CCVs were
purified from adult rat brains as described (18). To purify clathrin, coats
were stripped from the vesicles by incubation in buffer B (0.5 M Tris, pH
7.0, 2 mM EDTA, 0.83 mM benzamidine, 0.23 mM phenylmethylsulfonyl
fluoride, 0.5 g/ml aprotinin, and 0.5 g/ml leupeptin) for 15 min on ice.
The samples were then centrifuged for 15 min at 245,000  gmax with
the purified coat fraction remaining in the supernatant. The stripping
and centrifugation steps were repeated a second time and the superna-
tants were pooled. The pooled supernatants were loaded onto a contin-
uous 5–20% sucrose gradient made in buffer B and then centrifuged for
3.5 h at 195,000  gmax in a Sorvall Step Saver vertical rotor. Fractions
of 2 ml were collected and analyzed by SDS-PAGE and Coomassie Blue
staining. Peak clathrin fractions were pooled and dialyzed overnight in
clathrin assembly buffer (10 mM Tris-Cl, pH 8.5) and subsequently used
for clathrin assembly assays.
Clathrin assembly assays were performed with 0.5 M purified clath-
rin and different concentrations (0.12–2 M) of fusion proteins in a final
volume of 90 l of clathrin assembly buffer. Assembly was initiated at
4 °C by addition of 10 l of 1 M MES, pH 6.7. The mixture was kept on
ice for 45 min and then centrifuged at 400,000  gmax for 6 min. The
supernatant (80 l) was loaded on a SDS-PAGE and the clathrin as-
sembly was quantified by Coomassie Blue staining.
RESULTS
HIP1 and HIP12 Are Abundant Coat Proteins of CCVs of
Adult and Embryonic Rat Brains—Both HIP1 and HIP12 have
been implicated in clathrin-mediated endocytosis (4, 15–17,
19). To further characterize the endocytic functions of these
proteins, we sought to directly compare their biochemical and
functional properties. Both HIP1 and HIP12 are predomi-
nantly expressed in brain (1, 2). Within brain, however, the two
proteins demonstrate distinct developmental expression pro-
files (Fig. 1A). Specifically, HIP1 is most highly expressed
during early development, with the highest detectable levels at
embryonic day 13 (E13) and E16, whereas HIP12 expression is
only weakly detectable at E13 through E18 but increases in
postnatal day 2 rats with high levels of expression in adult
brain (Fig. 1A). Interestingly, both HIP1 and HIP12 are highly
enriched on the coats that are stripped from purified CCVs
prepared from E18 brains (data not shown) and adult brains
(Fig. 1B). HIP1 and HIP12 show a comparable enrichment in
the CCV fractions to both each other and to the coat proteins
clathrin and AP2 (data not shown and Fig. 1B). Moreover, both
proteins appear to be major components of the clathrin coats
(Fig. 1C). To make this determination, coat proteins stripped
from adult or E18 CCVs where fractionated on linear 5–20%
sucrose gradients, which readily separated HIP1 and HIP12
from the large subunits of the adpatin complexes (Fig. 1C).
Coomassie Blue staining of the fractions revealed that HIP1
and HIP12 where present on E18 or adult rat brain CCVs,
respectively, at near stoichiometric levels with adaptin sub-
units (Fig. 1C).
HIP1 and HIP12 Co-localize and Interact—Earlier work in
our laboratory has shown that HIP1 and HIP12 interact in the
yeast two-hybrid system (5). To confirm this interaction, co-
immunoprecipitation studies were performed in HEK-293T
cells. Immunoprecipitation of endogenous HIP1 with a mono-
clonal antibody led to co-immunoprecipitation of endogenous
HIP12 whereas no precipitation of HIP12 was seen in the
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absence of HIP1 antibody (Fig. 2A). Transfection of the cells
with HIP12 cDNA led to a significantly greater immunopre-
cipitation of HIP12 by endogenous HIP1 (Fig. 2A). We next
analyzed the intracellular localization of HIP1 and HIP12 in
neuronal NT2 cells following transfection of HA-tagged HIP12.
Confocal microscopy analysis of the expression of HIP12-HA
shows punctate staining throughout the cell and extensive
co-localization with endogenous HIP1 (Fig. 2B). These punctae
correspond predominantly to clathrin-coated pits and CCVs as
previously described (4, 15).
FIG. 1. HIP1 and HIP12 are coat proteins of CCVs and display distinct developmental expression profiles. A, post-nuclear superna-
tants (100 g) from brain extracts of various rat developmental stages were analyzed by Western blot with anti-HIP1 or anti-HIP12 antibodies as
indicated. E, embryonic day; P, post-natal day; A, adult. B, purified CCVs were obtained by subcellular fractionation of adult rat brain
homogenates. Aliquots (100 g) of the various fractions were analyzed by Western blot with antibodies against clathrin heavy chain (CHC), the
-adaptin subunit of AP2 (AP2), HIP1 and HIP12, as indicated. H, homogenate; P, pellet; S, supernatant; SGp, sucrose gradient pellet; SGs,
sucrose gradient supernatant; C, coats; V, vesicles. The coats and vesicles correspond to the supernatant and pellet fractions, respectively, following
incubation of the purified CCVs with 0.5 M Tris, pH 9.0. C, purified CCVs from adult and E18 brains were stripped of their coats in 0.5 M Tris, pH
7.0, 2 mM EDTA. Aliquots of the coat fractions were analyzed on SDS-PAGE and Coomassie Blue staining (panels at left). The coat proteins were
then fractionated on continuous 5–20% sucrose gradients. The gradients were collected in 20 equal fractions and aliquots from fractions 7–18 were
analyzed by SDS-PAGE with Coomassie Blue staining (Coomassie). The migration of HIP1 and HIP12 was determined by Western blot as
indicated. The bracket on the E18 gradient demonstrates the migratory positions of the large subunits of the adaptins, whereas the arrow indicates
the migratory position of HIP1.
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To determine the regions of HIP1 and HIP12 that mediate
their interaction, pull-down experiments were performed. Pre-
vious studies have shown that a small fragment of HIP12
encompassing the helical domain interacts with HIP1 in the
yeast two-hybrid system (5). Therefore, we analyzed whether
HIP1 and HIP12 interact through their helical domains. In
fact, the helical domains of both HIP1 and HIP12 are sufficient
to specifically pull-down HIP12 and HIP1, respectively (Fig.
2C). These studies suggest that the HIP1-HIP12 interaction
could affect specific functions of each protein.
HIP1 and HIP12 Display Differential Binding to Clathrin
and AP2—Between its ENTH and helical domains, HIP1 con-
tains a clathrin-box consensus sequence, LMDMD, which binds
to the terminal domain of the clathrin heavy chain (15). This
sequence is found in close association with the sequences
FDNKF, FDDIF, FGSSF, and DPF, which match consensus
sequences for binding to AP2 (17). Upon sequence alignment,
the LMDMD motif in HIP1 aligns with the sequence LIEIS in
HIP12 (Fig. 3A). The LIEIS sequence resembles a clathrin-box
motif similar to that found in the clathrin-binding proteins
ACK1 and ACK2 (20, 21). In contrast, the DPF motif is absent
from HIP12 and the FDNKF, FDDIF, and FGSSF sequences,
which match the consensus FX(N/D/S)X(F/L) (17), are not con-
served (Fig. 3A). We thus designed a HIP1-GST fusion protein,
GST-HIP1-(276–335), encompassing these sites (Fig. 3B) and
tested for its ability to bind clathrin and AP2 in comparison
with a GST fusion protein encoding the corresponding region of
HIP12, GST-HIP12-(302–348). As previously demonstrated
(15), GST-HIP1-(276–335) binds strongly to clathrin (Fig. 3C,
top panel). In contrast, GST-HIP12-(302–348) demonstrates
much weaker clathrin binding (Fig. 3C, top panel). In both
cases, the binding is mediated through the terminal domain of
the clathrin heavy chain (15) (data not shown). Moreover, GST-
HIP1-(276–335) binds strongly to AP2 whereas no binding of
GST-HIP12-(302–348) to AP2 was detected (Fig. 3C, bottom
panel).
In Contrast to HIP12, HIP1 Does Not Bind Actin—HIP12
binds actin through its talin-homology domain (4). To deter-
mine whether the talin homology domain of HIP1 also medi-
ates actin binding, a GST-HIP1-talin homology domain fusion
protein was analyzed for co-sedimentation with F-actin. As a
control, the talin homology domain of HIP12 was expressed as
a GST fusion protein and analyzed in parallel. Surprisingly, in
contrast to HIP12, HIP1 bind only very weakly to actin in vitro
(Fig. 4A). Specifically, in the presence of 5 M F-actin, 87.6% 
6.0 (mean  S.E., n  3) of GST-HIP12-talin homology domain
was bound to F-actin. In contrast, only 19.3%  3.7 (mean 
S.E., n 3) of the GST-HIP1-talin homology domain was bound
to the same amount of polymerized actin (Fig. 4B). A number of
different parameters such as pH and ion concentrations were
tested for their potential effect on the binding of HIP1-talin to
actin. However, none of these alterations allowed for increased
binding (data not shown). Consistent with this observation is
the lack of co-localization between the HIP1-talin homology
domain and the cortical actin cytoskeleton following overex-
pression of HIP1-talin in cultured cells (Fig. 4C). This is in
contrast to the observation that the talin homology domain of
HIP12 shows enrichment along cortical actin filaments (4).
HIP1 and HIP12 Contain a Second Clathrin-binding Site in
Their Helical Domain—We previously demonstrated that GST-
FIG. 2. HIP1 and HIP12 interact via their helical domains. A,
HEK 293T cells were transfected with full-length HIP12 cDNA (HIP12)
or were left untransfected (). Cell lysates were prepared and immu-
noprecipitations were carried out in the presence or absence (AB) of
mouse mAb HIP1#9. Cell lysate (SM) and immunoprecipitated protein
(IP) were analyzed by SDS-PAGE and Western blot with anti-HIP12FP
antibody. B, co-localization of transfected HIP12-HA (red) and endoge-
nous HIP1 (green) was analyzed in neuronal NT2 cells. Overlays of the
images are shown in the panel on the right (overlay). Scale bar 10 M.
C, HeLa cells were transfected with either HIP1 or HIP12 full-length
cDNA as indicated. Cell extracts were prepared and tested for binding
to GST alone or various HIP12 and HIP1 GST fusion proteins. Equal
volumes of unbound and bound proteins were analyzed by SDS-PAGE
and Western blot with anti-HIP1 and anti-HIP12 antibodies as
indicated.
FIG. 3. HIP1 and HIP12 display differential binding to clathrin
and AP2. A, sequence alignment of a region of HIP1 and HIP12 dem-
onstrating consensus clathrin and AP2-binding sites. B, schematic rep-
resentation of various GST fusion proteins used for the binding assays.
C, soluble proteins from brain extracts were affinity purified with equal
amounts of HIP1 or HIP12-GST fusion proteins bound to glutathione-
Sepharose beads. Proteins specifically bound to the beads were ana-
lyzed by Western blot with antibodies against CHC or the -adaptin
subunit of AP2 (AP2) as indicated.
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HIP1-(219–616), encompassing the clathrin box motif and the
helical domain, demonstrated stronger binding to clathrin than
GST-HIP1-(276–335) alone, encompassing only the clathrin
box consensus site (15). This observation led us to suggest the
presence of a second clathrin-binding site in the helical domain
of HIP1 (15). Moreover, the helical domains of HIP1 and HIP12
were recently reported to mediate binding to clathrin (16, 19).
We thus designed fusion proteins encompassing the helical
domains of HIP1, GST-HIP1-(336–610) and HIP12, GST-
HIP12-(349–644) (Fig. 5A) and tested their ability to bind
clathrin and AP2. Both fusion proteins show specific binding to
clathrin from brain extracts (Fig. 5B, top panel) but not to AP2
(Fig. 5B, bottom panel).
HIP1 and HIP12 Promote Clathrin Assembly through Their
Helical Domains—Full-length HIP12 stimulates clathrin as-
sembly (19). Moreover, both HIP1 and HIP12 contain a DLL
motif in their helical domains that contributes to the clathrin
assembly activity of other clathrin adaptor proteins (22). We
thus tested the ability of both of the helical domains to promote
clathrin assembly in vitro. Interestingly, both GST-HIP1-(336–
610) and GST-HIP12-(348–644) fusion proteins stimulated
clathrin assembly in a dose-dependent manner with full activ-
ity detected in the presence of 0.5 M fusion protein (Fig. 6). In
contrast, GST alone did not stimulate clathrin assembly (Fig.
6). These results demonstrate that like HIP12 (19), HIP1 stim-
ulates clathrin assembly, and that for both proteins, assembly
activity is localized to their helical domains, which demon-
strate weak clathrin binding.
HIP1 and HIP12 Bind Directly to Clathrin Light Chain—
Inspection of the helical domains of HIP1 and HIP12 failed to
reveal any type I or type II clathrin box sequences (23) that
could mediate interactions with the terminal domain of the
clathrin heavy chain. This suggested the possibility of a novel
form of clathrin interaction mediated by the helical domains.
To explore this further, we performed additional binding as-
says with GST-HIP1-(336–610) and GST-HIP12-(348–644).
Consistent with the lack of consensus clathrin terminal do-
main-binding sites, neither helical domain fusion protein
bound to purified His6-tagged clathrin terminal domain (Fig.
7A, bottom panel), whereas the same fusion proteins bound to
clathrin heavy chain from brain extracts (Fig. 7A, top panel).
Clathrin exists in the cytosol of cells as a triskelia, in which
three molecules of clathrin heavy chain are associated with
three molecules of clathrin light chain (24). Thus, it is possible
that the helical domain fusion proteins bind to clathrin light
chain leading to an indirect interaction with the heavy chain.
This idea is supported by the recent observation that addition
of light chains to truncated clathrin cages restores their ability
to bind HIP12 (19). To directly test if the helical domains of
HIP1 and HIP12 bind to clathrin light chain, we generated a
His6-tagged fusion protein encoding full-length clathrin light
chain b. Interestingly, this purified fusion protein bound
strongly to the HIP1 and HIP12 helical domain GST fusion
proteins (Fig. 7B). Taken together, these studies demonstrate
that the helical domains of HIP1 and HIP12 do not interact
with the clathrin heavy chain via its terminal domain, al-
though we cannot rule out the possibility that they could in-
teract with the proximal or distal legs of the heavy chain. In
contrast, HIP1 and HIP12 bind directly to the clathrin light
chain through the helical domains, which also stimulate clath-
rin assembly.
FIG. 4. HIP1 does not bind actin in contrast to HIP12. A, binding
of the HIP1-talin homology domain expressed as a GST fusion protein
(HIP1-talin) to filamentous actin was analyzed by cosedimentation in
the presence of various concentrations of assembled actin (0–10 M).
Binding of the HIP12-talin homology domain GST fusion protein
(HIP12-talin) was used as positive control. The arrows indicate HIP1 or
HIP12 fusion proteins in the supernatant (S) and pellet (P) fractions. B,
the percentage of GST-HIP1-talin bound to actin is shown as mean 
S.E. of three independent experiments. C, HeLa cells expressing a
FLAG-tagged construct encoding the HIP1-talin homology domain
(HIP1-talin-Flag) were immunostained with an anti-FLAG antibody
shown in green and with Texas Red-phalloidin shown in red to reveal
F-actin. Overlays of the confocal images are shown in the right. Scale
bar  10 M.
FIG. 5. The helical domains of HIP1 and HIP12 bind to clathrin
but not AP2. A, schematic representation of various GST fusion pro-
teins used for the binding assays. B, soluble proteins from brain ex-
tracts were affinity purified with equal amounts of HIP1 or HIP12 GST
fusion proteins bound to glutathione-Sepharose beads. Proteins specif-
ically bound to the beads were analyzed by Western blot with antibodies
against CHC or the -adaptin subunit of AP2 (AP2) as indicated.
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DISCUSSION
Many proteins involved in clathrin-mediated endocytosis
harbor a facet of protein interaction modules that enable them
to function in the recruitment of clathrin triskelia to sites of
endocytosis and in the subsequent formation of CCVs, shedding
of coat proteins, and intracellular transport of the uncoated
vesicle (25, 26). In the present work, we show that two family
members, HIP1 and HIP12, are major components of CCVs. As
such, they are comparable in their enrichment on purified
vesicles to the coat proteins -adaptin, clathrin, and AP180. In
contrast, accessory proteins of clathrin-mediated endocytosis
such as dynamin, synaptojanin, amphiphysin I and II, epsin,
endophilin, and Eps15 are far less enriched on CCVs (27).
Moreover, HIP1 and HIP12 are present on CCVs at near stoi-
chiometric levels with the adaptor proteins. Finally, both pro-
teins can be stripped from purified vesicles by treatment with
Tris buffer, which is well established to remove coat compo-
nents from vesicles (28). Thus, HIP1 and HIP12 should be
considered as novel members of the clathrin coat.
Several endocytic accessory proteins that participate in the
formation of clathrin-coated pits and CCVs contain a tandem
arrangement of high affinity clathrin and AP2 consensus-bind-
ing sites including amphiphysin I (29), epsin (30), and arrestins
(31). This tandem arrangement of consensus sites is also found
in HIP1 but is not conserved in the HIP1 family member
HIP12. HIP12 does not contain the DPF/W or FX(N/D/S)X(F/L)
consensus AP2-binding sites (17, 32, 33) and correspondingly
does not show binding to AP2. Moreover, the clathrin box motif
that is present in HIP12 binds clathrin with rather low affinity.
Since the tandem arrangement of clathrin- and AP2-binding
sites is thought to stabilize clathrin/adaptor interactions (30),
HIP12 probably contributes less to the stabilization of this
FIG. 6. HIP1 and HIP12 promote clathrin assembly through
their helical domains. An aliquot of the purified clathrin used as a
starting material (SM) for the clathrin assembly assays was resolved on
SDS-PAGE and stained with Coomassie Blue. Clathrin assembly as-
says were performed with increasing amounts of fusion proteins GST,
GST-HIP1-(336–610), and GST-HIP12-(348–644) as indicated. The
GST fusion proteins and the clathrin remaining in the supernatant
after high-speed centrifugation following initiation of clathrin assembly
were analyzed by SDS-PAGE and Coomassie Blue staining.
FIG. 7. HIP1 and HIP12 bind directly to the clathrin light chain through their helical domains. A, soluble proteins from brain extracts
or purified His6-tagged clathrin terminal domain (TD) fusion protein were affinity purified with equal amounts of HIP1 or HIP12 GST fusion
proteins bound to glutathione-Sepharose beads. Proteins specifically bound to the beads were analyzed by Western blots with antibodies against
CHC or the His epitope (tetra-HIS) as indicated. B, purified His6-tagged clathrin light chain b (LCb) fusion protein was affinity purified with equal
amounts of HIP1 or HIP12 GST fusion proteins bound to glutathione-Sepharose beads. Proteins specifically bound to the beads were analyzed by
Western blot with the anti-His epitope antibody (tetra-HIS).
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protein complex. As such, HIP12 is comparable with amphiphy-
sin II that interacts with clathrin through type I and type II
clathrin box sequences but does not bind to AP2 (34, 35).
The formation of clathrin-coated pits does not occur ran-
domly. Instead, defined sites of endocytosis exist that are de-
marcated by AP2 (36) with extended areas of the membrane not
being involved in coated pit formation (37). It has been pro-
posed that the underlying membrane cytoskeleton contains
coated pit-nucleation sites and that actin may be involved in
the spatial organization of endocytic components at the mem-
brane (37, 38). Interestingly, both HIP1 and HIP12 contain an
ENTH domain, a PtdIns(4,5)P2-binding motif that is found in
several other coat and accessory proteins including AP180 and
epsins (11, 12). Recent studies have demonstrated that
PtdIns(4,5)P2 is localized predominantly on the plasma mem-
brane of quiescent neurons but that its levels are increased on
endocytic membranes following stimulation of endocytic activ-
ity (39). In addition to potential PtdIns(4,5)P2 binding, HIP1
and HIP12 contain a talin homology domain that in HIP12
binds directly to actin (4). Thus, it is intriguing to speculate
that HIP1 and HIP12 may play a role in the coordination of
clathrin, actin, and PtdIns(4,5)P2 functions at the plasma
membrane to demarcate sites of clathrin assembly. Surpris-
ingly, however, HIP1 does not bind to actin. This appears to
result from the observation that a helical segment at the N
terminus of the talin homology domain of HIP1 can disrupt
actin binding through an intrasteric interaction (40). Neverthe-
less, heterodimerization of HIP1 and HIP12 may be a mecha-
nism that allows HIP1 to indirectly bind to F-actin and that
also allows AP2 to be recruited to clathrin nucleation sites
defined by the HIP proteins at the plasma membrane.
Consistent with a role for the HIP1-HIP12 complex in defin-
ing endocytic active zones, HIP12 has been demonstrated to
stimulate clathrin assembly (19). Here, we have determined
that HIP1 also functions in clathrin assembly and that for both
proteins assembly activity is localized to the helical domain.
GST fusion proteins encoding the helical domains of HIP1 and
HIP12 are also able to affinity purify clathrin triskelia from
brain extracts. Interestingly, the helical domains do not bind to
the terminal domain of the clathrin heavy chain but do bind
directly to the clathrin light chain, consistent with recent re-
sults demonstrating that light chains are necessary for HIP12
binding to clathrin hub domains (19). Clathrin triskelia, com-
posed of three heavy chains, each with a bound light chain,
assemble into a polyhedral lattice at physiological pH only in
the presence of assembly proteins such as AP2 or AP180. In-
terestingly, it has been proposed that the light chains interact
with the distal legs of the clathrin heavy chains to prevent
clathrin assembly (41). Specifically, the recombinant hub frag-
ments of the clathrin heavy chains assemble in the absence of
light chains at physiological pH whereas addition of purified
light chains blocks the assembly reaction (41). Moreover, Src-
dependent phosphorylation of the clathrin heavy chain at ty-
rosine 1477, a site that appears to be involved in binding to
light chain, stimulates clathrin assembly, possibly by releasing
the inhibitory effect of the light chain (42). Thus, HIP1 and
HIP12 may stimulate clathrin assembly by interacting with the
clathrin light chain and through an unknown mechanism re-
lease light chain-mediated inhibition allowing the heavy chains
to interact and assemble (41). This model is consistent with the
observation that overexpression of HIP12 in cultured cells
causes a mislocalization of the light chains without a major
effect on the distribution of the heavy chains (19). HIP1 and
HIP12 are the first assembly proteins demonstrated to interact
directly with clathrin light chain and this interaction appears
to reveal a novel mechanism involved in the regulation of
clathrin assembly.
Growing evidence suggests a role for the disease-associated
protein huntingtin in clathrin-mediated endocytosis and intra-
cellular vesicle transport. For example, huntingtin associates
with the -adaptin C subunit of the AP2 complex (43) and with
endophilin A3 (44) and it associates with vesicles and microtu-
bules (44–47). The interaction of huntingtin with AP2 and
endophilin suggests that huntingtin participates in the com-
plex network of interactions regulating clathrin-mediated en-
docytosis and vesicle recycling. Huntingtin has been localized
to endosomal and lysosomal membranes (48) and it is present
but not enriched on purified CCVs (46) (data not shown). In-
triguingly, the interaction of HIP1 with huntingtin is directly
modulated by polyglutamine expansion in huntingtin, suggest-
ing that disturbances in protein interaction and subsequent
alterations in clathrin-mediated endocytosis could contribute
to the pathogenesis of Huntington disease.
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